Growth and Transformation - diagnosed 3-6 years

Pilares del viaje de transición

Esta sesión está destinada a familias/cuidadores de adolescentes y adultos con Duchenne. Cubre cuatro pilares del viaje transicional de Duchenne: Continuidad de la atención, Planificación del estilo de vida, Éxito financiero y Escuela/Carrera/Pasatiempos, y es seguido por una sesión de discusión/Preguntas y respuestas.

Pradeep P.A. Mammen, MD, FACC, FAHA

Associate Professor of Medicine and Co-Director

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Director for Translational Research for the Advanced Heart Failure and Transplant Cardiology Program, UT Southwestern Medical Center

Kent Williams, MD

Pediatric Gastroenterologist

Nationwide Children's Hospital

Jennifer Shumsky, BSN, RN, CHCO, PACS

Director, Payer Relations

Little Hercules Foundation

Hawken Miller

Content Strategist

CureDuchenne

Pillars of the Early Journey

This session is intended for families/caregivers of children and adolescents with Duchenne. It covers four pillars of the early Duchenne journey: Multidisciplinary Care, Steroids, Nutrition, and Involvement in Clinical Trials, and is followed by a discussion/Q&A session.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

Diana Castro, MD

Associate Professor of Pediatrics, Neurology and Neurotherapeutics

University of Texas Southwestern

Kindann Fawcett, PhD

Post Doctoral Fellow

University of Arkansas for Medical Sciences

Pillars of the Transition Journey

This session is intended for families/caregivers of teens and adults with Duchenne. It covers four pillars of the transitional Duchenne journey: Continuity of Care, GI-related Care, Medical Privacy, and School/Career/Hobbies, and is followed by a discussion/Q&A session.

Pradeep P.A. Mammen, MD, FACC, FAHA

Associate Professor of Medicine and Co-Director

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Director for Translational Research for the Advanced Heart Failure and Transplant Cardiology Program, UT Southwestern Medical Center

Hawken Miller

Content Strategist

CureDuchenne

Jennifer Shumsky, BSN, RN, CHCO, PACS

Director, Payer Relations

Little Hercules Foundation

Kent Williams, MD

Pediatric Gastroenterologist

Nationwide Children's Hospital

REGENXBIO

RGX-202:  REGENXBIO’s investigational gene therapy for the treatment of Duchenne Muscular Dystrophy presented by:  Johannaz (Naz) Dastgir, DO, Senior Director, Clinical Development Lead at REGENXBIO

A program update on RGX-202, REGENXBIO’s investigational gene therapy program for the treatment of Duchenne.

Contact: Duchenne@regenxbio.com or patientadvocacy@regenxbio.com

Johannaz Dastgir, DO

Senior Director, Clinical Development Lead

REGENXBIO